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Neuroblastoma (NB) is one of the most common solid tumours
usually affecting children in the first years of life. Approximately
30% of patients are under 1 year at the time of diagnosis
(Bernstein et al, 1992). In infants, the most frequent stages are
stage 1 (35%) followed by stage 4-s (20%) and stage 4 (14%)
(Castel Sanchez et al, 1997). When Evans et al (1971) proposed a
staging system for neuroblastoma, they gave a clear definition of
stage 4-s disease. Essentially observed in infants under 1 year-of-
age, this special stage was defined as disease that would otherwise
be stage 1 or 2, but with dissemination confined to one or more of
the following sites: liver, skin or bone marrow (without radiolog-
ical evidence of bone metastases at complete skeletal survey). The
revised International Neuroblastoma Staging System (Brodeur et
al, 1993) stipulated an upper limit at 10% of bone marrow involve-
ment for stage 4-s disease. Thus, infants with stage 4 disease are
patients with metastatic disease which does not correspond to the
4-s definition.
Recently described genetic markers are being analysed exten-
sively in children over 1 year with stage 4 neuroblastoma, but their
prognostic significance remains unclear.
The overriding objectives of the present study were to undertake
an analysis of prognostic factors in an unselected cohort of infants
with stage 4 neuroblastoma, and especially to assess the prognostic
significance of MYCN amplification (MNA) and bone lesions in
this population.
In 1990, a national prospective study (NBL 90) was initiated
that was to include all consecutive infants with metastatic NB
diagnosed in the member institutions of the French Society of




Between February 1990 and February 98, 21 member institutions
of the SFOP participated in this study. All infants under 1 year-of-
age with newly diagnosed stage 4 neuroblastoma were eligible
for entry. Previous chemotherapy was an exclusion criterion,
but primary surgery was not. Data concerning all infants were
reviewed to verify their consistency with the revised International
Neuroblastoma Staging System (INSS) and Response Criteria
(INRC) for diagnosis, staging and assessment of response
(Brodeur et al, 1993). A total of 55 infants were enrolled in the
study. Four were ineligible, due to uncertainty regarding compli-
ance and follow-up evaluation (n = 3), or to insufficient available
data (n = 1). The present analysis therefore concerns 51 infants. It
reports the outcome of infants as of November 1998, 9 months
after inclusion of the last case.
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Summary To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51
infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the
primary tumour. Group I comprised 21 infants with radiologically detectable bone lesions, Group II 22 patients with an unresectable primary
tumour and Group III eight patients with only metaiodobenzylguanidine (MIBG) skeletal uptake. MYCN oncogene content was assayed in
47/51 tumours and found to be amplified in 17 (37%). The 5-year event-free survival (EFS) rate of these 51 infants was 64.1% (± 7.1%). In a
univariate analysis, bone lesions, MYCN amplification, urinary vanillylmandelic/homovanillic acid ratio and serum ferritin levels adversely
influenced outcome. In the multivariate analysis, radiologically detectable bone lesions were the most powerful unfavourable prognostic
indicator: the EFS rate was 27.2% for these infants compared to 90% for infants without bone lesions (P < 0.0001). Our data emphasize the
poor prognosis of infants affected by stage 4 NB with bone lesions, especially when associated with MYCN amplification. Given the poor
results in this group whatever the treatment, new therapeutic approaches need to be investigated in the future. © 2000 Cancer Research
Campaign
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doi: 10.1054/ bjoc.2000.1412, available online at http://www.idealibrary.com on The diagnosis of neuroblastoma was based on conclusive clin-
ical, laboratory and imaging findings and was always confirmed
by histology and/or cytology. The primary tumour was evaluated
by computed tomography scan or magnetic resonance imaging
(MRI) and/or ultrasonography and iodine123 or 131metaiodobenzyl-
guanidine (MIBG) scintigraphy (McEwan et al, 1985). The
complete metastatic work-up included a skeletal study by MIBG
(or a Technetium99m scan in the absence of MIBG-uptake at
the site of the primary tumour), a complete examination of the
skeleton by X-rays and extensive bone-marrow staging (according
to INSS criteria). When MIBG-uptake was detected in metastases,
several views were obtained to confirm that uptake was exclu-
sively localized in the skeleton and not in soft tissues. In addition,
the films and scans were centrally reviewed if MIBG scan showed
uptake in one or several skeletal sites. Urinary vanillylmandelic
(VMA) and homovanillic (HVA) acid levels and dopamine excre-
tion according to creatinine concentration (Bertani-Dziedzic et al,
1990) were measured, as were serum neuron-specific enolase
(NSE) (Zeltza et al, 1986), ferritin (Hahn et al, 1980), and lactate
dehydrogenase (LDH) (Shuster et al, 1992) levels.
Analysis of the MYCN oncogene was planned for all tumours.
Results were considered reliable only if tumour material exhibited
over 10% of neuroblasts. MYCN genomic content was determined
by Southern or slot blot using MYCN second exon probes. MYCN
amplification (MNA) was defined as ≥ 10 copies per haploid
genome. Other biological investigations such as evaluation of the
DNA index (Look et al, 1984) or a search for deletion of the short
arm of chromosome 1 (Caron, 1993) were optional.
Labreveux de Cervens et al (1994) defined three groups of
infants with stage 4 neuroblastoma. These groups appeared
different in terms of median age, response to chemotherapy and
long-term survival. In our study, the 51 infants with stage 4 disease
were then divided into these three groups:
Group I comprised 21 infants whose bone lesions were detected
by X-ray. None of these patients had a normal skeletal MIBG scan
(or Tc99m scan); they all exhibited skeletal uptake.
Group II comprised 22 infants with metastatic disease but with no
detectable bone lesion neither by MIBG nor by X-ray. The primary
tumour in this group was considered unresectable and associated
with metastases, especially in the liver, skin, or slight bone-
marrow involvement. Tumours were defined as unresectable when
they traversed and invaded the midline structures, usually those
encasing large vessels, or when their size, structure, or location
prohibited surgery without a high risk of rupture or major surgical
complications. The latter included some large thoracic tumours
that compressed the upper respiratory tract without necessarily
crossing the midline extensively. All dumbell tumours, with or
without neurologic impairment, were deemed unresectable (Rubie
et al, 1997).
Group III consisted of eight infants, in which bone lesions were
not detected by X-ray but the MIBG scan showed uptake in one 
or several skeletal sites. This group includes patients with 
MIBG features consistent with cortical bone disease and those
with features consistent with bone marrow involvement.
Thus, 51 evaluable infants with stage 4 disease entered the
study, 21 had radiologically detectable bone lesions and 30 had not




Group I Chemotherapy consisted of four courses of cyclophos-
phamide–doxorubicin–vincristine CAdO (Coze et al, 1997),
followed by surgery if complete remission was obtained at all
metastatic sites and high-dose chemotherapy (HDC) with stem cell
transplantation (SCT) in case of MNA. In the event of no response
or progressive disease after the first two courses of CAdO, treat-
ment was switched for etoposide and platinum compounds, as in
the case of patients with stage 4 neuroblastoma over 1 year-of-age
(Coze et al, 1997), followed by surgery and HDC with SCT if
complete remission (CR) or partial remission (PR) was obtained.
Group II These patients received the same treatment as that
administered for localized unresectable neuroblastoma.
Chemotherapy consisted of two courses of carboplatin and etopo-
side (Frappaz et al, 1992), followed by two courses of CAdO. All
patients received four courses of chemotherapy, and radical
surgery was then attempted. After surgery, chemotherapy was
indicated for residual disease and/or lymph-node involvement
(one course of each combination).
Group III Treatment of these patients was left to the discretion of
the physician. Patients were treated either like stage 4-s (Michon et
al, 1993) or like stage 4 without HDC if MYCN was not amplified
(MNN). In keeping with the NBL 90 protocol, stage 4-s lesions
were treated according to the evolutionary course of the disease.
Initial treatment included six courses of cyclophosphamide and
vincristine (CO), followed by surgery. If no response was obtained
or disease progressed after CO, second-line therapy using irradia-
tion or chemotherapy was given, followed by surgical excision of
the primary tumour.
According to the NBL90 protocol, all patients with metastatic
neuroblastoma (groups I, II and III) and MNA received high-dose
chemotherapy followed by SCT.
Radiotherapy
After November 1992, because of a high incidence of local
relapses, locoregional irradiation was recommended for infants
whose tumour exhibited MNA, regardless of age or the quality of
the surgical excision. A total dose of 25 Gy was delivered in daily
fractions of 1.5–1.8 Gy each.
Evaluation of reponse to therapy
Response to therapy was assessed according to INSS criteria
(Brodeur et al, 1971). Response was defined as follows: complete
remission (CR) = no detectable disease; very good partial remis-
sion (VGPR) = only a small local tumour residue (< 10% of the
initial size) but no detectable disease at any site of metastasis;
partial remission (PR) ≥ 50% reduction of all measurable and
evaluable disease. All other situations were considered as failures
(mixed response (MR), no response (NR) and progressive disease
(PD)). Tumour response was evaluated during and at the end of
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HDC, and at least every 3 months thereafter.
Statistical analysis
A comparison of infants whose tumours were MYCN amplified
(MNA) and those whose tumours were not MYCN amplified
(MNN) was performed for each variable with the χ 2 test corrected
for heterogeneity or Fisher’s exact test (Peto et al, 1977). The
probabilities of survival were calculated from the time-of-
diagnosis to relapse, or death, or last follow-up, according to the
Kaplan–Meir product-limit method (Fleiss, 1981). In the event-
free-survival (EFS) analysis, disease progression or relapse, 
and death, whatever the reasons, were considered as events.
Multivariate assessment of EFS was performed using Cox’s
proportional hazards model and curves were compared using the
log-rank test (Cox, 1977).
RESULTS
Patient characteristics
Patient characteristics are listed in Table 1. The median age was 7
months (range: newborn–12 months). The primary tumour was
abdominal in 37 patients (73%). Ten children had a dumbbell
tumour (seven thoracic, one cervical, one abdominal, and one
pelvic tumour). Forty-five of 51 patients with metastatic disease
had multiple sites of metastasis. The bone marrow (n = 36) and the
liver (n = 25) were the most frequently involved. MYCN oncogene
content was assayed in 47 tumours and found to be amplified
(≥ 10 copies) in 17 (37%).
Neuroblastoma stage 4 with bone lesions (group I)
The bone metastases of the 21 patients in this group were detected
by both X-ray and MIBG or Tc99m scan. Patient characteristics are
listed in Table 2. The sex ratio was 16 males/5 females, and the
median age was 9 months (range = 1–12 months). The primary
tumour was abdominal in 20 patients. All these 21 patients had a
single or multiple bone lesions on X-ray films. Three of them
presented a single site of uptake on MIBG scan (and one or several
radiologically detectable bone lesions), whereas 17 had multiple
sites of osteomedullary uptake. One last patient had a negative
MIBG scan even at the primary tumour site, but the Tc99m bone
scan showed a single positive lesion. MYCN oncogene content
was found to be amplified (≥ 10 copies) in 13/21 (62%).
Seven of these 21 infants achieved a CR of all metastatic sites
following first-line chemotherapy. Four of them were consolidated
with high-dose chemotherapy (HDC) because of MYCN amplifi-
cation. Of these four, two are alive in first CR with a follow-up of
69 and 9 months post-diagnosis, one died of infection 28 months
after HDC, and one relapsed 7 months after HDC and died. One
other patient with MNA, who was not consolidated, relapsed 2
months after surgery and died. The two patients with MNN who
achieved a CR were treated with conventional chemotherapy and
surgery. One of them is alive in first CR having attained a follow-
up of 75 months, and the other died of treatment-related complica-
tion after HDC performed in second PR.
The fate of the other 14 patients was as follows: in one, disease
progressed rapidly during induction and he died. One infant died
of infection after two courses of CAdO. The twelve remaining
infants achieved a partial response (PR) of their metastases after
first-line chemotherapy (CAdO). Two of them (MNA) died of
disease progression, and ten achieved a CR or VGPR on second-
line therapy (etoposide/platinum). Nine of these ten were further
consolidated with HDC. Four of them are alive and free of disease
(> 64, 49, 22 and 12 months) (three MNN) and the other five died
of disease. The remaining patient (MNN), who entered VGPR
after second-line therapy, was not consolidated with HDC and is
alive and free of disease (> 65 months).
Hence 8/21 patients with bone lesions are alive and free of
disease, of whom three had MNA and five have MNN tumour.
Neuroblastoma stage 4 without bone lesion (group II
and III)
Group II
Bone metastases were not detectable either by X-ray or MIBG
scan in the 22 infants in this group (Table 2). The sex ratio was 8
males/14 females, and the median age was 4 months (range = 0–
11 months). The primary tumour was abdominal in 12 patients,
thoracic in five, cervical in two, cervico-thoracic in two and pelvic
in one. A dumbbell tumour was found in seven patients. MYCN
oncogene content was assayed in 18/22 tumours and found to be
amplified in four (22%).
Ten infants without MYCN amplification were treated
according to the NBL90 protocol. All are alive in first CR with a
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Median ((min–max) months) 7 (0–12)
Mean ((standard deviation) months) 6.3 (3.7)
< 6 months 23 45





Size of primary tumour
T1: < 5 cm 7 14
T2: 5–10 cm 34 66
T3: > 10 cm 8 16
Multiple 2 4
Group
Group I (bone lesions) 21 41
Group II (unresectable primary tumour) 22 43
Group III (MIBG skeletal uptake) 8 16
Metastases
Bone 21 41
Bone marrow 36 70
Liver 25 49
Subcutaneous nodules 10 20
Intraparenchymal CNS 2 4
Others 3 6
Elevated NSE (> 2N) (n = 37 measured) 31 84
Elevated LDH (> 2N) (n = 38 measured) 14 37
Elevated Ferritin (> 2N) (n = 36 measured) 6 17
Elevated urinary catecholamine excretion HVA/VMA > 1 26 51
MYCN oncogene analysis (47 measured) > 10 copies 17 36follow-up of 5–68 months post-diagnosis. Four other infants, with
an MNN tumour, were treated like stage 4-s disease (protocol
violations). Only one achieved a CR and is alive and free of
disease (> 25 months). Disease progressed on therapy in the other
three and they entered CR after second-line therapy and are alive
(> 82, 25 and 6 months). Of the four other infants with MNA
tumour, two were consolidated and are alive and free of disease
(> 51 and 44 months). The third was treated only with the conven-
tional NBL90 chemotherapy and he is alive in first CR (> 53
months). The fourth patient died of a surgical complication during
initial biopsy.
The MYCN status was unknown (MNU) in four patients
because the tumour-cell content of the sample was poor (n = 2), or
because it was not analysed (n = 2). One of them died of sepsis
after four courses of chemotherapy. Another, treated according to
the protocol, is alive in first CR with a follow-up of 65 months.
The remaining two patients were treated like stage 4-s disease and
are alive and free of disease (> 69 and 33 months).
In summary, in this group, 20/22 infants are alive in CR or PR,
of whom 14 had an MNN tumour, three an MNA tumour and three
were MNU.
Group III
Skeletal MIBG uptake was evidenced in eight infants, but their X-
ray films were normal. The sex ratio was 5 males/3 females, and
the median age was 5 months (range = 0–11 months). The primary
tumour was retroperitoneal in five patients. Two patients presented
a single site of uptake on the skeletal MIBG scan, whereas six
patients had multiple sites of osteomedullary uptake. No patient
had an MNA tumour.
Four patients were treated according to the protocol used for
stage 4 disease without HDC and are alive and free of disease in
first CR (> 91, 71, 40 and 31 months). The four others received the
same treatment administered for stage 4-s disease: one died of
progression despite a second-line therapy and three are alive (> 85,
42 and 17 months), two of whom have remained in PR despite
combination chemotherapy, radiotherapy and surgery.
Seven of eight infants are therefore alive in CR or PR in this
group.
Prognostic factors
The factors likely to influence event-free survival (EFS) were first
studied by univariate analysis (logrank test). Factors which were
significant or of borderline significance were further analysed by
multivariate analysis. The projected overall survival and EFS rates
at 5 years are 67.2% (± 6.1%) and 64.1% (± 7.1%) for all 51
infants with stage 4 neuroblastoma. The results of the univariate
analysis are given in Table 3. The comparison of EFS between
patients with or without MNA indicated significantly poorer
survival in the subgroup with an MNA tumour (P = 0.0004)
(Figure 1). However, the most powerful prognostic indicator was
bone lesions (Figure 2): indeed EFS was far better in the 30 infants
without a bone lesion compared to the 21 with bone lesions (90%
(± 5.5%) vs 27.2% (± 10.6%), P < 0.0001). Regarding tumour
markers, only the serum ferritin level and VMA/HVA ratio
appeared to affect outcome, particularly when ferritin was over
twice the normal value (P = 0.008). Conversely, sex, age-at-
diagnosis, the site of the primary tumour, as well as histologically
proven lymph-node involvement, had no impact on outcome.
Multivariate analysis was performed using the Cox regression
method with stratification on age, size and the site of the primary
tumour, MNA and bone lesions. The only significant prognostic
factor was bone lesions (P = 0.001), with a relative risk of 12.06
(95% CI, 2.71–53.5). The EFS rate at 5 years is 11.7% (± 10.6%)
for the MNA subgroup with bone lesions and 75% (± 21.7%) for
the MNA subgroup without bone lesions. This difference is not
statistically significant (P = 0.10) due to the small number of
infants.
DISCUSSION
To our knowledge, this is the first multicentre prospective study to
focus on infants with metastatic neuroblastoma (NB) with the aim
of evaluating both the clinical relevance of MYCN amplification
and of bone lesions in such a population. Two groups were defined
based on radiological findings, the first comprising infants with
bone lesions detected by X-ray (group I) and the second those with
no radiologically detected bone lesion (groups II and III).
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Table 2 Patient characteristics according to bone lesions
Stage IV with bone Stage 4 without bone
Factor lesions lesion P
Cases (n)2 1 3 0
Sex Male/Female 16/21 13/30 0.02
Age
median (months (min–max)) 9 (0–12) 4 (0–11) < 0.0001
< 6 months 3/21 20/30
Site of primary tumour = abdomen 20/21 17/30 0.01
Metastases
Bone marrow 18 18 0.047
Liver 6 19 0.01
Subcutaneous nodules 3 7 0.49
Intraparenchymal CNS 2 0 0.16
Others 2 1 0.56
Elevated NSE (> 2N (n = 37 measured) 14/18 17/19 > 0.99
Elevated Ferritin (> 2N) (n = 36 measured) 4/15 2/21 0.09
Elevated LDH (> 2N) (n = 38 measured) 8/19 6/19 0.08
Urinary catecholamine excretion
HVA/VMA < 1 16/21 10/30 0.002
MYCN oncogene analysis (47 measured)
> 10 copies 13/21 4/26 0.001Our patient characteristics were comparable to those of other
published studies (Paul et al, 1991; Labreveux de Cervens et al,
1994; Strother et al, 1995; Lampert et al, 1997). The classic prog-
nostic factors analysed in NB to date were the focus of this study.
In terms of age at diagnosis, other authors have already under-
scored the existence of a more favourable prognosis for disease in
younger infants (0–6 months) (De Bernardi et al, 1992; Labreveux
de Cervens et al, 1994). De Bernardi et al (1992) published that
infants who were 6–11 months old with stage 4 disease had the
worst prognosis. In a smaller series, De Cervens et al (1994)
further substantiated this conclusion, but in their study stage 4
patients were not only the oldest but also had bone lesions. Our
data confirm that infants with bone lesions are indeed the oldest, as
were those with MNA tumours, however age in itself had no
impact whatsoever on outcome in the univariate analysis.
With respect to sex as prognostic factor, some investigators have
suggested that it has an effect on survival conferring a more
favourable outcome on females (Carlsen et al, 1985). An excess of
male patients in our study did in fact have stage 4 NB and bone
lesions but this did not lead to a difference in survival between
genders; male and female patients had similar survival rates in the
univariate analysis.
The site as a prognostic factor has also been purported to impact
on survival. Goon et al (1984) found that neuroblastoma confined
to the thorax have the most favourable outcome. In our study, the
primary sites were not statistically different between the three
groups and had no effect on outcome.
Evidence for the prognostic significance of MYCN oncogene
amplification is inconsistent and controversial. MYCN was found
to be correlated with a poor prognosis in neuroblastoma (Seeger et
al, 1985; Nakagawara et al, 1987; Look et al, 1991; Brodeur et al,
1992) and was demonstrated to be the most relevant adverse prog-
nostic indicator in localized NB (Rubie et al, 1997). The legiti-
macy of this finding however has remained open to debate in
patients with stage 4 disease > 1 year-of-age. MYCN amplification
has also been singled out as conferring a poor prognosis (Bowman
et al, 1997; Dubois et al, 1999) in patients with stage 4 NB under 1
Stage 4 NB <1 year with MNA and/or bone lesions 977
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Table 3 Prognostic factors: univariate analysis
Factor n patients (n events) P (log-rank)
Sex
Male 29 (10) 0.99
Female 22 (7)
Age
< 6 months 23 (5) 0.16
> 6 months 28 (12)
Site of primary tumour
Abdominal 37 (15) 0.14
Nonabdominal 14 (2)
Bone lesions
Yes 21 (14) < 0.0001
No 30 (3)
Size of primary tumour





HVA/VMA > 1 26 (13) 0.008
HVA/VMA < 1 25 (4)
NSE (n = 37)
Normal 6 (0) NE
Abnormal > 2N 31 (9)
Ferritin (n = 36)
Normal 30 (6) 0.0008
Abnormal > 2N 6 (5)
LDH (n = 38)
Normal 24 (5) 0.17
Abnormal > 2N 14 (6)
NMA (n = 47)
< 10 copies 30 (5) 0.0004
> 10 copies 17 (11)













Figure 1 Event-free survival according to MYCN status;   MYCN
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Figure 2 Evert-free survival according to bone lesions;   No bone lesion;
   Bone lesionsyear, but this finding was not corroborated by others (Lampert et
al, 1997). Indeed, Lampert et al (1997) reported no difference in
the probability of survival between infants with stage 4 NB, with
or without a MYCN amplified tumour. In their recent study,
Dubois et al (1999) showed that MYCN amplification correlated
with increased frequency of bone and intracranial or orbital metas-
tases. In our study, MYCN amplification as a univariate factor
correlated significantly with survival (P = 0.0004) (Figure 1) and
MNA and bone lesions were also significantly correlated (P =
0.001) (Table 2).
Although certain other biological prognostic indicators, such as
serum ferritin and urinary catecholamine excretion (HVA/VMA
ratio) appeared to be significant in the univariate analysis, they
were finally of marginal importance in the multivariate analysis.
This was related to the fact that the VMA/HVA ratio was signifi-
cantly correlated with bone lesions and MNA, and that there were
major variations between serum ferritin determinations between
the different centres.
Event-free survival rate at 5 years is 64.1% (± 7.1%) for our
entire study population. Paul et al (1991) reported a similar 5-year
EFS (75%) for 24 patients and, given the favourable outcome of
this series of infants with metastatic NB < 1 year-of-age, did not
advocate using HDC in these patients. Strother et al (1995)
reported a 5-year actuarial survival rate of 60% for 58 patients.
Although survival rates appear comparable, these authors did not
analyse the prognostic value of bone lesions, which was the
strongest prognostic indicator in the multivariate analysis in our
study. Based on our findings, we consider that patients < 1 year
with stage 4 NB with bone lesions should be distinguished from
patients with the same disease stage and age but no bone lesions,
because their outcome is totally different and, as a consequence,
the former require more aggressive treatment. Evans et al (1971)
already demonstrated that overt bone lesions in infants, which
were to be clearly distinguished from bone-marrow involvement
without positive radiological findings, virtually always portended
a fatal outcome. Since then, the difference between stage 4-s and 4
disease has been clearly established. In addition, MIBG scintig-
raphy has made it possible to identify a specific group of infants
whose X-rays are normal but in whom osteomedullary MIBG
uptake is evidenced (group III in this study). Our data suggest that
disease in this specific group differs from that of stage 4 NB with
radiologically detectable bone lesions because the long-term
outcome appears better than that of patients with radiologically
detectable bone lesions. Moreover, the prognosis appears to be
different from that of stage 4-s disease. In our opinion, the prog-
nosis in group III is similar to that of stage 4-s when bone marrow
involvement exceeds the 10% limit stipulated for classification as
4-s by the INSS (Brodeur et al, 1993). We consider skeletal MIBG
uptake to be related to greater bone-marrow involvement, which
would account for its role as a prognostic factor. Like stage 4 NB,
this stage with MIBG uptake alone requires more aggressive
conventional chemotherapy to achieve a complete remission.
With respect to infants affected by a stage 4 unresectable
primary tumour (group II), our study confirms the excellent
outcome of this stage at this age (< 1 year) (Labreveux de Cervens
et al, 1994). Indeed, only toxicity is incriminated in the 2/22 deaths
in group II. The treatment and the prognosis of this stage are the
same as that of stage 3 neuroblastoma in patients under 1 year-
of-age at diagnosis (Rubie et al, 1997). According to the three
groups, three different treatment regimens were used for this 
study in which prognostic factors were analysed. Hence, stage 4
neuroblastoma with bone lesions were treated with the most
aggressive therapy. Despite the fact that treatment is an important
part of outcome, in this series patients with bone lesions had the
worst prognosis.
Finally, this study has shown that radiologically detectable bone
lesions are a strong prognostic factor conferring a very poor prog-
nosis on infants with bone lesions, especially when their tumours
are MNA. Given the poor results of this group, whatever the treat-
ment, new therapeutic approaches need to be investigated in the
future.
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